RT Journal Article
SR Electronic
T1 Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.16.21253686
DO 10.1101/2021.03.16.21253686
A1 Yelin, Idan
A1 Katz, Rachel
A1 Herzel, Esma
A1 Berman-Zilberstein, Tamar
A1 Ben-Tov, Amir
A1 Kuint, Jacob
A1 Gazit, Sivan
A1 Patalon, Tal
A1 Chodick, Gabriel
A1 Kishony, Roy
YR 2021
UL http://medrxiv.org/content/early/2021/05/24/2021.03.16.21253686.abstract
AB Vaccinations are considered the major tool to curb the current SARS-CoV-2 pandemic. A randomized placebo-controlled trial of the Pfizer BNT162b2 vaccine has demonstrated a 95% efficacy in preventing COVID-19 disease. These results are now corroborated with statistical analyses of real-world vaccination rollouts, but resolving vaccine effectiveness across demographic groups and its interaction with comorbidities is challenging. Here, applying a multivariable logistic regression analysis approach to a large patient-level dataset, including SARS-CoV-2 tests, vaccine inoculations and personalized demographics, we model vaccine effectiveness at daily resolution and its interaction with sex, age and comorbidities. Vaccine effectiveness gradually increased post day 12 of inoculation, then plateaued, around 35 days, reaching 95.0% [CI 93.4%-96.3%] for all infections and 99.5% [CI 97.0%-99.9%] for symptomatic infections. While effectiveness was on average uniform for men and women, it declined mildly but significantly with age especially for males. Effectiveness further declined for people with type 2 diabetes, COPD, and immunosuppression, as well as cardiac disease in females. Quantifying real-world vaccine effectiveness, including both biological and behavioral effects, our analysis provides initial measurement of vaccine effectiveness across demographic groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3633/19) within the KillCorona-Curbing Coronavirus Research Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of Maccabi Healthcare Services, Tel-Aviv, Israel. The IRB includes an exempt from informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified data should be referred to Maccabitech, Maccabi Healthcare Services Institute for Research & Innovation.